Analyzing the Estrogen Receptor Status of Liver Metastases with [F]-FES-PET in Patients with Breast Cancer.

Background: Positron emission tomography (PET) with 16α-[F]-fluoro-17β-estradiol ([F]-FES) can visualize estrogen receptor (ER) expression, but it is challenging to determine the ER status of liver metastases, due to high physiological [F]-FES uptake. We evaluated whether [F]-FES-PET can be used to determine the ER status of liver metastases, using corresponding liver biopsies as the gold standard.

Methods: Patients with metastatic breast cancer ( = 23) were included if they had undergone a [F]-FES-PET, liver metastasis biopsy, CT-scan, and [F]-FDG-PET.

Value of F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study.

Breast cancer (BC) is a heterogeneous disease in which estrogen receptor (ER) expression plays an important role in most tumors. A clinical dilemma may arise when a metastasis biopsy to determine the ER status cannot be performed safely or when ER heterogeneity is suspected between tumor lesions. Whole-body ER imaging, such as 16α-F-fluoro-17β-estradiol (F-FES) PET, may have added value in these situations.

The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.

Purpose: To determine the value of prebiopsy F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in discriminating malignant from benign vertebral bone lesions.

Materials And Methods: This retrospective study included 53 patients with 55 vertebral bone lesions that underwent FDG-PET/CT before CT-guided biopsy. Pathologic examination of the biopsy sample and a minimum follow-up of 1 year were used as reference standard.

The diagnostic significance of repeat ultrasound-guided biopsy of musculoskeletal soft-tissue lesions with initially inconclusive biopsy results.

Introduction: To determine the diagnostic yield of repeat ultrasound (US)-guided biopsy of musculoskeletal soft-tissue lesions with initially inconclusive biopsy results, and to explore predictive factors for success of repeat biopsy.

Materials And Methods: This retrospective study included 42 patients who underwent a repeat (second) US-guided biopsy session to target a musculoskeletal soft-tissue lesion because an initial US-guided biopsy session provided inconclusive results. Both biopsy sessions were performed in a tertiary referral center for soft-tissue sarcomas.